Gilead, Gala­pa­gos re­port com­pet­i­tive num­bers for first big PhI­II read­out for fil­go­tinib in rheuma­toid arthri­tis

Gilead $GILD and its part­ners at Gala­pa­gos $GLPG of­fered their first cut of Phase III da­ta for fil­go­tinib, their late-stage can­di­date for dis­rupt­ing the rheuma­toid arthri­tis mar­ket. And while they may have come in nu­mer­i­cal­ly a lit­tle be­hind their big ri­val at Ab­b­Vie, re­searchers seem to have gained a good safe­ty pro­file and some com­pet­i­tive num­bers that help jus­ti­fy Gilead’s $725 mil­lion up­front near­ly 3 years ago.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER